Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies (CGT), and Lonza have entered a partnership to integrate industry-leading solutions in CGT. The goal of the collaboration is to improve efficiency across the CGT supply chain, inclusive of apheresis network management, healthy donor tissue supply, manufacturing and, where appropriate, supply chain management and logistics.

The partnership establishes Be The Match BioTherapies and Lonza as preferred partners and is aimed at supporting the companies’ shared goal of providing end-to-end solutions that streamline the development of cell and gene therapies across the CGT supply chain. Lonza and Be The Match BioTherapies will integrate each other’s services in their respective offerings to provide a seamless offering to customers.

This collaboration builds on current partnerships announced by Lonza and Be The Match BioTherapies to build a seamless, vein-to-vein network for customers and their patients. Partners of Lonza include Cryoport, a leading temperature-controlled supply chain company, and Vineti, a company developing the first commercial, configurable, cloud-based digital platform to orchestrate advanced therapy supply chains. Be The Match BioTherapies brings expertise in successfully delivering more than 100,000 cell therapies, expertise in logistics, managing apheresis networks, and the ability to provide high-quality cellular source material from the Be The Match Registry which offers the world’s largest, most ethnically diverse listing of more than 22 million potential blood and marrow donors, with Lonza’s industry-leading capabilities in cell and gene therapy manufacturing.

“Be The Match BioTherapies brings deep experience in overcoming supply chain and logistical challenges impacting developers of cell and gene therapies, including factors that delay patients’ ability to access the treatments they need,” said Alberto Santagostino, senior vice president, head of cell and gene therapy, Lonza. “We’re pleased to add their team to our growing network of strategic partners and look forward to working together to cultivate a more seamless, streamlined ecosystem for cell and gene therapy development.”

Chris McClain, senior vice president, sales and new business development, Be The Match BioTherapies, said, “Lonza plays a central role in Be The Match BioTherapies’ pursuit of accelerating patient access to high-quality manufactured cell therapies. This collaboration will allow our teams to combine our substantial expertise and resources across the cell therapy supply chain to ease the logistical burden for cell and gene therapy developers globally. By offering the ability to leverage a fully integrated cell and gene therapy supply chain, we can ultimately provide a brighter future for patients.”